Innosuisse launched a call for projects for the Swiss Accelerator in 2022 as a transitional measure for Horizon Europe. Following a three-stage assessment process, Innosuisse has now approved 53 innovation projects, among which there are four Wyss Zurich (three alumni and one current) projects in Life Sciences.
Three independent experts evaluated each of the 752 short applications and the 128 full applications. Of these, 64 selected companies gave an application presentation in the third round before the Innovation Council made a final decision. The total funding granted amounts to CHF 112 million of which 10 million were allocated to the four Wyss Zurich projects (CUTISS AG, hemotune AG, HYLOMORPH AG and Nanoflex Robotics AG).